MX2024006573A - Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15. - Google Patents
Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15.Info
- Publication number
- MX2024006573A MX2024006573A MX2024006573A MX2024006573A MX2024006573A MX 2024006573 A MX2024006573 A MX 2024006573A MX 2024006573 A MX2024006573 A MX 2024006573A MX 2024006573 A MX2024006573 A MX 2024006573A MX 2024006573 A MX2024006573 A MX 2024006573A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- antibodies
- antibody
- antigen
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284937P | 2021-12-01 | 2021-12-01 | |
| PCT/US2022/080542 WO2023102367A1 (en) | 2021-12-01 | 2022-11-29 | B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006573A true MX2024006573A (es) | 2024-06-11 |
Family
ID=84519919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006573A MX2024006573A (es) | 2021-12-01 | 2022-11-29 | Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230312724A1 (https=) |
| EP (1) | EP4441093A1 (https=) |
| JP (1) | JP2024543942A (https=) |
| KR (1) | KR20240112342A (https=) |
| CN (1) | CN118339184A (https=) |
| AR (1) | AR127806A1 (https=) |
| AU (1) | AU2022402985A1 (https=) |
| CA (1) | CA3238965A1 (https=) |
| CO (1) | CO2024008181A2 (https=) |
| IL (1) | IL313159A (https=) |
| MX (1) | MX2024006573A (https=) |
| TW (1) | TW202346320A (https=) |
| WO (1) | WO2023102367A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US9422351B2 (en) * | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| PL3094351T3 (pl) * | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
| WO2016040724A1 (en) * | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| EP3728705A4 (en) * | 2017-12-18 | 2022-01-19 | Charles River Laboratories, Inc. | RADICALLY DIVERSE HUMAN ANTIBODY LIBRARY |
| CN116693686A (zh) * | 2018-02-11 | 2023-09-05 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| AU2019228381B2 (en) * | 2018-02-28 | 2021-12-16 | Pfizer Inc. | IL-15 variants and uses thereof |
-
2022
- 2022-11-29 CA CA3238965A patent/CA3238965A1/en active Pending
- 2022-11-29 AU AU2022402985A patent/AU2022402985A1/en active Pending
- 2022-11-29 MX MX2024006573A patent/MX2024006573A/es unknown
- 2022-11-29 IL IL313159A patent/IL313159A/en unknown
- 2022-11-29 KR KR1020247021496A patent/KR20240112342A/ko active Pending
- 2022-11-29 TW TW111145737A patent/TW202346320A/zh unknown
- 2022-11-29 US US18/059,548 patent/US20230312724A1/en active Pending
- 2022-11-29 AR ARP220103274A patent/AR127806A1/es unknown
- 2022-11-29 WO PCT/US2022/080542 patent/WO2023102367A1/en not_active Ceased
- 2022-11-29 EP EP22823298.9A patent/EP4441093A1/en active Pending
- 2022-11-29 JP JP2024532180A patent/JP2024543942A/ja active Pending
- 2022-11-29 CN CN202280079188.6A patent/CN118339184A/zh active Pending
-
2024
- 2024-06-24 CO CONC2024/0008181A patent/CO2024008181A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023102367A1 (en) | 2023-06-08 |
| TW202346320A (zh) | 2023-12-01 |
| CO2024008181A2 (es) | 2024-06-27 |
| JP2024543942A (ja) | 2024-11-26 |
| US20230312724A1 (en) | 2023-10-05 |
| EP4441093A1 (en) | 2024-10-09 |
| KR20240112342A (ko) | 2024-07-18 |
| IL313159A (en) | 2024-07-01 |
| AR127806A1 (es) | 2024-02-28 |
| AU2022402985A1 (en) | 2024-07-11 |
| CN118339184A (zh) | 2024-07-12 |
| CA3238965A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
| MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
| MX2022010664A (es) | Materiales y métodos para modular una respuesta inmunitaria. | |
| EA201390278A1 (ru) | Антитела к ох40 и способы их применения | |
| MX2024003355A (es) | Anticuerpos anti-cd3. | |
| RU2012143793A (ru) | Биспецифические двухвалентные антитела анти-vegf/анти-ang-2 | |
| EP2352523A4 (en) | IMPROVED ANTI-CD19 ANTIBODIES | |
| NO20083053L (no) | Humane monoklonale antistoffer mot O8E | |
| MX2009002418A (es) | Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso. | |
| MX2011012039A (es) | Anticuerpos bloqueadores anti-dkk-1 y sus usos. | |
| EA201101242A1 (ru) | Полностью человеческие антитела, специфические для cadm1 | |
| SA522440646B1 (ar) | أجسام مضادة ترتبط بـ siglec15 واستخداماتها | |
| MX2022013894A (es) | Anticuerpos neutralizantes que se unen a la proteina s del sars-cov-2. | |
| MY210018A (en) | Monoclonal antibody that binds specifically to gitr | |
| AU2019433019A8 (en) | Antibodies binding CD40 and uses thereof | |
| MX2022014243A (es) | Proteina de union al antigeno st2. | |
| DE60315815D1 (de) | ANTAGONISTISCHE HUMANE ANTI-hFAS-LIGAND-ANTIKÖRPER UND FRAGMENTE DAVON | |
| MX2025003153A (es) | Anticuerpos anti-ccr8 | |
| ZA202308896B (en) | Antibodies binding trop2 and uses thereof | |
| TW200635946A (en) | Binding proteins specific for human matriptase | |
| ZA202408388B (en) | Antibodies targeting sirp-alpha and uses thereof | |
| MX2024011805A (es) | Nuevos anticuerpos anti-fgfr2 |